DELCATH SYSTEMS INC (DCTH) Stock Price, Quote, News and Overview
NASDAQ:DCTH - Nasdaq - US24661P8077 - Common Stock - Currency: USD
DCTH Quote, Performance and Key Statistics
14.88
-0.66 (-4.25%)
The current stock price of DCTH is 14.88 USD. In the past month the price decreased by -7.75%. In the past year, price increased by 244.44%.
DCTH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About DCTH
Company Profile
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 76 full-time employees. The company went IPO on 2000-10-19. The firm's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Company Info
DELCATH SYSTEMS INC
566 Queensbury Avenue
Queensbury NEW YORK 10019 US
CEO: Gerard Michel
Employees: 76
Company Website: https://delcath.com/
Investor Relations: http://delcath.com/investors/
Phone: 15187438892
DELCATH SYSTEMS INC / DCTH FAQ
What is the stock price of DELCATH SYSTEMS INC today?
The current stock price of DCTH is 14.88 USD. The price decreased by -4.25% in the last trading session.
What is the ticker symbol for DELCATH SYSTEMS INC stock?
The exchange symbol of DELCATH SYSTEMS INC is DCTH and it is listed on the Nasdaq exchange.
On which exchange is DCTH stock listed?
DCTH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DELCATH SYSTEMS INC stock?
12 analysts have analysed DCTH and the average price target is 22.23 USD. This implies a price increase of 49.41% is expected in the next year compared to the current price of 14.88. Check the DELCATH SYSTEMS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DELCATH SYSTEMS INC worth?
DELCATH SYSTEMS INC (DCTH) has a market capitalization of 475.71M USD. This makes DCTH a Small Cap stock.
How many employees does DELCATH SYSTEMS INC have?
DELCATH SYSTEMS INC (DCTH) currently has 76 employees.
What are the support and resistance levels for DELCATH SYSTEMS INC (DCTH) stock?
DELCATH SYSTEMS INC (DCTH) has a support level at 13.18 and a resistance level at 16.28. Check the full technical report for a detailed analysis of DCTH support and resistance levels.
Is DELCATH SYSTEMS INC (DCTH) expected to grow?
The Revenue of DELCATH SYSTEMS INC (DCTH) is expected to grow by 1628.05% in the next year. Check the estimates tab for more information on the DCTH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DELCATH SYSTEMS INC (DCTH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DCTH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DCTH, evaluating the profitability, health, valuation and growth aspects
- DELCATH SYSTEMS INC (DCTH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DELCATH SYSTEMS INC (DCTH) Sales and EPS estimates to see what analysts future expectations are.
- DELCATH SYSTEMS INC (DCTH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DELCATH SYSTEMS INC (DCTH) Insider and Institutional Ownership to learn about the owners and their transactions.
- DELCATH SYSTEMS INC (DCTH) Stock Chart to make your own analysis
- DELCATH SYSTEMS INC (DCTH) Latest news and press-releases to stay up to date.
Does DELCATH SYSTEMS INC (DCTH) stock pay dividends?
DCTH does not pay a dividend.
When does DELCATH SYSTEMS INC (DCTH) report earnings?
DELCATH SYSTEMS INC (DCTH) will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of DELCATH SYSTEMS INC (DCTH)?
DELCATH SYSTEMS INC (DCTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.35).
What is the Short Interest ratio of DELCATH SYSTEMS INC (DCTH) stock?
The outstanding short interest for DELCATH SYSTEMS INC (DCTH) is 3.29% of its float. Check the ownership tab for more information on the DCTH short interest.
DCTH Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DCTH. When comparing the yearly performance of all stocks, DCTH is one of the better performing stocks in the market, outperforming 98.45% of all stocks.
DCTH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DCTH. DCTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DCTH Financial Highlights
Over the last trailing twelve months DCTH reported a non-GAAP Earnings per Share(EPS) of -1.35. The EPS increased by 62.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -107.71% | ||
| ROE | -398.13% | ||
| Debt/Equity | 0 |
DCTH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to DCTH. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 72.73% and a revenue growth 1628.05% for DCTH